Heavy Chain Diseases

Author(s):  
Maxime Seligmann

1989 ◽  
Vol 140 (5-6) ◽  
pp. 487-502 ◽  
Author(s):  
M. Cogné ◽  
J.-L. Preud'homme ◽  
P. Guglielmi


2004 ◽  
pp. 420-428
Author(s):  
Jean-Paul Fermand ◽  
Jean-Claude Brouet


1998 ◽  
pp. 1053-1056
Author(s):  
Jean-Louis Preud'homme


1979 ◽  
Vol 48 (1) ◽  
pp. 145-167 ◽  
Author(s):  
Maxime Seligmann ◽  
Edith Mihaesco ◽  
Jean-Louis Preud'homme ◽  
Franqoise Danon ◽  
Jean-Claude Brouet


1975 ◽  
Vol s1-6 (1) ◽  
pp. 65-71 ◽  
Author(s):  
E C Franklin


Author(s):  
James R. Cook




Author(s):  
L. Lopez-Anglada ◽  
N. Puig ◽  
M. Diez-Campelo ◽  
L. Alonso-Ralero ◽  
S. Barrena ◽  
...  


Blood ◽  
2011 ◽  
Vol 117 (26) ◽  
pp. 6991-6998 ◽  
Author(s):  
Daniel Corcos ◽  
Michael J. Osborn ◽  
Louise S. Matheson

Heavy chain diseases (HCDs) are B-cell proliferative disorders characterized by the production of monoclonal, incomplete, immunoglobulin (Ig) heavy chains (HCs) without associated light chains (LCs). These abnormal HCs are produced as a consequence of HC gene alterations in the neoplastic B cells. HC gene alterations will also impact on surface HC, which is part of the B-cell receptor (BCR), a crucial player in lymphocyte activation by antigen. The selective advantage conferred to mutant cells by abnormal BCR without an antigen-binding domain may be explained by activation of ligand-independent signaling, in analogy to what has been shown for mutated oncogenic growth factor receptors. Here we review data obtained from mouse models showing abnormal, constitutive activity of HCD-BCR, and we discuss the possible mechanism involved, namely, aberrant spontaneous self-aggregation. This self-aggregation might occur as a consequence of escape from the chaperone immunoglobulin binding protein (BiP) and from the anti-aggregation effect of LC association. The concept of misfolding-induced signaling elaborated here may extend to other pathologies termed conformational diseases.



Sign in / Sign up

Export Citation Format

Share Document